Abstract:Abstract Background Coronavirus disease 2019 (COVID-19) is associated with excess risk of cardiovascular events in the early post-infection period and during convalescence. Despite the progress in our understanding of cardiovascular complications, uncertainty persists with respect to contemporary event rates particularly given the change in viral variants and COVID-19 therapies, as well as availability of vaccines in later months of the pandemic. Purpose To report the cardiovascular complications of COVID-19, and assess results by vaccination status from a large multicenter patient-level US registry. Methods Adult patients with polymerase chain reaction-confirmed COVID-19 who received inpatient or outpatient care at Mass-General Brigham (MGB) Health system, the largest health system in Massachusetts that serves 1.5 million patients, were eligible for inclusion. Data elements were entered into a centralized database by trained research staff. Each clinical event was adjudicated by two independent physicians. The primary outcome was major cardiovascular events, defined as venous or arterial thrombosis, myocarditis or heart failure with inpatient treatment, new atrial fibrillation/flutter, or cardiovascular death. Outcomes were assessed at 30- and 90-day follow-up, shown as cumulative incidence, represented by subdistribution hazard functions. Findings were pre-specified to be assessed separately for patients who were hospitalized with COVID-19 vs outpatients. Vaccination status was ascertained for subgroup-specific analyses. Results The study included 4,123 patients from the MGB Health System from 3/13/2020 through 06/03/2022 (mean age: age: 53.5 ± 18 years; 55.9% female, Table). Among hospitalized patients, the cumulative incidence of primary outcome was 17.4% at day 30 (95% CI: 15.2-19.5%). Respective 30-day event rates for outpatients were 1.1% (95% CI: 0.7%-1.5%) (Figure, Panel A). Cumulative incidence of 30-day outcomes based on vaccination status (restricted to cohort from 12/14/2020 onward) is summarized in Panel B. Conclusions This multicenter study suggests that 30-day adjudicated cardiovascular events were frequent in hospitalized patients with COVID-19, although event rates were lower in vaccinated patients. Follow-up for 90-day outcomes is being finalized and will be presented at ESC 2023.Table 1.Figure 1.

Abstract WP260: Higher Incidence of Cerebral Venous Thrombosis Seen During the First Year of the COVID-19 Pandemic: Insights From the National Inpatient Sample

Trends in Cerebral Venous Thrombosis Before and During the COVID-19 Pandemic: Analysis of the National Inpatient Sample

Abstract WMP49: Outcomes of Patients With Cerebral Venous Thrombosiswith and Without COVID-19 Infection

Comparative Study of Cerebral Venous Thrombosis-Risk Factors, Clinical Course, and Outcome in Subjects with and without COVID-19 Infection

Abstract TP180: Characteristics and Outcomes of Cerebral Venous Sinus Thrombosis Associated With COVID-19

Trends in the Diagnosis of Pediatric Venous Thromboembolism and Arterial Ischemic Stroke during the COVID-19 Pandemic: An Administrative Database Study

Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19

Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales

Incidence of Thrombosis in COVID-19 Patients Compared to Non-COVID-19 Sepsis Patients in the Intensive Care Unit

Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients

Thromboembolic Disease and COVID-19: Experience of a University and Emergency Hospital During the Pandemic

Intracardiac Thrombus in COVID-19 Inpatients: A Nationwide Study of Incidence, Predictors, and Outcomes

Adjudicated cardiovascular events in a cotemporary multicenter cohort of patients with COVID-19: findings from the CORONA-VTE Registry

The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients

Death and Venous Thromboembolism Analyses among Hospitalized COVID-19-Positive Patients: A Multicenter Study

Predictors and mortality risk of venous thromboembolism in patients with COVID-19: systematic review and meta-analysis of observational studies

Venous Thromboembolism in Patients Hospitalized for COVID-19 in a Non-Intensive Care Unit

A Nationwide Cohort Study Assessing One-Year Cardiovascular and Thromboembolic Risks After Severe COVID-19 Compared to Matched Controls

An Interrupted Time-Series Analysis of the Impact of COVID-19 on Hospitalizations for Vascular Events in 3 Canadian Provinces

Venous Thromboembolism in Non-Covid-19 Population During the Pandemic: a Nationwide Multicenter Retrospective Survey

Venous and Arterial Thrombosis in Ambulatory and Discharged COVID-19 Patients: A Systematic Review and Meta-analysis